632 related articles for article (PubMed ID: 26452447)
1. Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?
Egan KB; Miner MM; Suh M; McVary K; Ni X; Roehrborn CG; Wittert G; Wong DG; Rosen RC
Andrology; 2015 Nov; 3(6):1165-72. PubMed ID: 26452447
[TBL] [Abstract][Full Text] [Related]
2. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
5. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
Chapple CR; Roehrborn CG; McVary K; Ilo D; Henneges C; Viktrup L
Eur Urol; 2015 Jan; 67(1):114-122. PubMed ID: 25301757
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
[TBL] [Abstract][Full Text] [Related]
8. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
[TBL] [Abstract][Full Text] [Related]
9. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
[TBL] [Abstract][Full Text] [Related]
11. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
12. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
Yokoyama O; Ozeki A; Suzuki N; Murakami M
Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.
Fusco F; D'Anzeo G; Henneges C; Rossi A; Büttner H; Nickel JC
PLoS One; 2015; 10(8):e0135484. PubMed ID: 26284523
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
16. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
[TBL] [Abstract][Full Text] [Related]
17. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
[TBL] [Abstract][Full Text] [Related]
19. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
[TBL] [Abstract][Full Text] [Related]
20. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
Jhang JF; Liao CH; Kuo HC
Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
